Positive interaction between 5-FU and FdUMP[10] in the inhibition of human colorectal tumor cell proliferation

Antisense and Nucleic Acid Drug Development

Volumn 9, Issue 5, 1999, Pages 481-486

  Liu, Jinqian ^a,b   Kolath, Jeff ^b   Anderson, James ^b   Kolar, Carol ^a   Lawson, Terrence A ^a,b   Talmadge, James ^a   Gmeiner, William H ^a,b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA AT OMAHA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; FLOXURIDINE PHOSPHATE; FLUOROURACIL; THYMIDYLATE SYNTHASE INHIBITOR;

APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CELL PROLIFERATION; CELL VIABILITY; CELLULAR DISTRIBUTION; CLONOGENIC ASSAY; COLORECTAL TUMOR; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG FORMULATION; HUMAN; HUMAN CELL; METABOLIC ACTIVATION; PRIORITY JOURNAL; TUMOR CELL;

EID: 0032718831     PISSN: 10872906     EISSN: None     Source Type: Journal    
DOI: 10.1089/oli.1.1999.9.481     Document Type: Article

References (25)

1. COPUR, S., AIBA, K, DRAKE, J.C., ALLEGRA, C.J., and CHU, E. (1995). Thymidylate synthase gene amplification in human colon cancer cell lines resistant to 5-fluorouracil. Biochem. Pharmacol., 49, 1419-1426.
2. CROOKE, S.T. (1992). Therapeutic applications of oligonucleotides. Annu. Rev. Pharmacol. Toxicol. 32, 329-376.
3. DAMHA, M.J., GIANNARIS, P.A., and ZABARYLO, S.V. (1990). An improved procedure for derivatization of controlled-pore glass beads for solid phase oligonucleotide synthesis. Nucleic Acids Res. 18, 3813-3821.
4. GMEINER, W.H. (1995). Delivery of traditional anti-cancer drugs as oligodeoxynucleotides. Cancer Watch 4, 120-121.
5. GMEINER, W.H., SAHARABUDHE, P.V., and PON, R.T. (1994). Synthesis of 5′-O-(4,4′-dimethoxytrityl)-2′-O-(tert-butyldimethylsilyl)-5- fluorouridine 3′-(cyanoethyl N,N-diisopropylphosphoramidite) and its use in the synthesis of RNA. J. Org. Chem., 59, 5779-5783.
6. GMEINER, W.H., SAHASRABUDHE, P., PON, R.T., SONNTAG, J., SRINIVASAN, S., and IVERSEN, P.L. (1995). Preparation of oligomeric 2′-deoxy-5-fluorouridylate of defined length and backbone composition: A novel pro-drug form of the potent anti-cancer drug 2′-deoxy-5-fluorouridylate. Nucl. Nuct. 14, 243-253.
7. HOUGHTON, J.A., WEISS, K.D., WILLIAMS, L.G., TORRANCE, P.M., and HOUGHTON, P.J. (1986). Relationship between 5-fluoro2′-deoxyuridylate, 2′-deoxyuridylate, and thymidylate synthetase activity subsequent to 5-fluorouracil administration, in xenografts of human colon adenocarcinomas. Biochem. Pharmacol. 35, 1351-1358.
8. HOUGHTON, J.A., HARWOOD, F.G., and HOUGHTON, P.J. (1994). Cell cycle control processes determine cytostasis or cytotoxicity in thymineless death of colon cancer cells. Cancer Res. 54, 4967-4973.
9. LIU, J., SKRADIS, A., KOLAR, C., KOLATH, J., ANDERSON, J., LAWSON, T., TALMADGE, J., and GMEINER, W.H. (1999). Increased cytotoxicity and decreased in vivo toxicity of FdUMP [10] relative to 5-FU. Nucl. Nuct. 18, 1789-1802.
10. MATSUOKA, H., UEO, H., SUGIMACHI, K., and AKIYOSHI, T. (1992). Preliminary evidence that incorporation of 5-fluoruracil into RNA correlates with antitumor response. Cancer Invest. 10, 265-269.
11. MOERTEL, C.G., FLEMING, T.R., MACDONALD, J.S., HALLER, D.G., LAURIE, J.A., GOODMAN, P.J., UNGERLEIDER, J.S., EMERSON, W.A., TORMEY, D.C., GLICK, J.H., VEEDER, M.H., and MAILLIARD, J.A. (1990). Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N. Engl. J. Med. 322, 352-358.
12. MOERTEL, C.G., FLEMING, T.R., MACDONALD, J.S., HALLER, D.G., LAURIE, J.A., TANGEN, C.M., UNGERLEIDER, J.S., EMERSON, W.A., TORMEY, D.C., GLICK, J.H., VEEDER, M.H., and MAILLIARD, J.A. (1995). Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann. Int. Med. 122, 321-326.
13. PARKER, W.B., and CHENG, Y.C. (1990). Metabolism and mechanism of action of 5-fluorouracil. Pharmac. Ther. 48, 383-395.
14. PRATT, W.B., RUDDON, R.W., ENSMINGER, W.D., and MAYBAUM, J., eds. (1994). The Anticancer Drugs, 2nd edition. (Oxford Press, New York), pp. 69-107.
15. SAHASRABUDHE, P.V., and GMEINER, W.H. (1997). Solution structures of 5-fIuorouracil-substituted RNA duplexes containing G-U wobble base pairs. Biochemistry 36, 5981-5991.
16. SAHASRABUDHE, P.V., PON, R.T., and GMEINER, W.H. (1995). Effects of site-specific substitution of 5-fIuorouridine on the stabilities of duplex DNA and RNA. Nucleic Acids Res. 23, 3916-3921.
17. SAHASRABUDHE, P.V., PON, R.T., and GMEINER, W.H. (1996). Solution structures of 5-fIuorouracil-substituted DNA and RNA decamer duplexes. Biochemistry 35, 13597-13608.
18. SANTI, D.V., and MCHENRY, C.S. (1972). 5-Fluoro-2′-deoxyuridylate covalent complex with thymidylate synthase. Proc. Natl. Acad. Sci. USA 69, 1855-1857.
19. SANTI, D.V., McHENRY, C.S., and SOMMER, H. (1974). Mechanism of interaction of thymidylate synthetase with 5-fluoradeoxyuri/dylate 13, 471-478.
20. SENDEROFF, R.I., WEBER, P.A., SMITH, D.R., and SOKOLOSKI, T.D. (1990). Evaluation of anti-proliferative agents using a cell-culture model. Invest. Ophthalmol. Vis. Sci. 31, 2572-2578.
21. SPIEGELMAN, S., NAYAK, R., SAWYER, R., STOLFI, R., and MARTIN, D. (1980). Improving the anti-tumor activity of 5-fluorouracil by increasing its incorporation into RNA via metabolic modulation. Cancer (Phila.) 45, 1129-1134.
22. TEW, K.D., HOUGHTON, P.J., and HOUGHTON, J.A. (1991). Preclinical and Clinical modulation of Anticancer Drugs. (CRC Press, Boca Raton, FL).
23. WECKBECKER, G. (1991). Biochemical pharmacology and analysis of fluoropyrimidines alone and in combination with modulators. Pharmac. Ther. 50, 367-424.
24. WOLMARK, N., FISHER, B., ROCKETTE, H., REDMOND, C., DEUTSCH, M., WICKERHAM, D.L., FISHER, E.R., CAPLAN, R., JONES, J., LERNER, H., LAWRENCE, W., PRAGER, D., WEXLER, M., EVANS, J., CRUZ, A., DIMITROV, N., JOCHIMSEN, P., and OTHER NSABP INVESTIGATORS. (1992). Postoperative adjuvant chemotherapy or BCG for colon cancer: results from NSABP protocol C-01. J. Natl. Cancer Inst. 80, 30-36.
25. WOLMARK, N., ROCKETTE, H., FISHER, B., WICKERHAM, D.L., REDMOND, C., FISHER, E.R., JONES, J., MAMOUNAS, E.P., ORE, L., PETRELLI, N.J., SPURR, C.L., DIMITROV, N., ROMOND, E.H., SUTHERLAND, C.M., KARDINAL, C.G., DEFUSCO, P.A., and JOCHIMSEN, P. (1993). The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J. Clin. Oncol. 11, 1879-1887.